HBM9161 + methylprednisolone

HBM9161 + methylprednisolone is a **combination therapy** of two distinct pharmaceuticals: HBM9161, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn), and methylprednisolone, a synthetic corticosteroid with anti-inflammatory and immunosuppressive activity. - **HBM9161** works by binding FcRn and blocking its interaction with IgG, leading to a reduction in circulating IgG. This mechanism is relevant in treating IgG-mediated autoimmune diseases. HBM9161 is under investigation for generalized myasthenia gravis and other autoimmune conditions, and has demonstrated dose-dependent, reversible suppression of total IgG in humans[1][3]. - **Methylprednisolone** is a classic anti-inflammatory glucocorticoid used to treat a variety of autoimmune, allergic, and inflammatory disorders. It binds intracellular glucocorticoid receptors, modulates gene expression, downregulates proinflammatory cytokines, and suppresses immune cell activation[2][4][6]. There are currently no approved products with the exact combination as a fixed-dose medication; the combination is likely being explored within clinical settings for synergistic immunomodulation in diseases such as generalized myasthenia gravis.

Brand names

MedrolMedrol DosepakMethylPREDNISolone Dose Pack